Men in their 40s and 50s tend to deal with a cluster of concerns at the same time: disrupted sleep from nighttime bathroom trips, questions about flagging energy and testosterone, vague worries about circulation. The supplement market has an answer for all of it, usually packaged with sweeping claims and thin evidence.<\/p>\n
eDrugstore’s Men’s Health Bundle takes a different approach. It combines three separate supplements targeting distinct but related systems: prostate health (ProstaJet with beta-sitosterol), nitric oxide and blood flow support (L-arginine and L-citrulline), and DHEA testosterone support.<\/p>\n
Each one addresses a real biological mechanism. Here’s what the research actually shows for each.<\/p>\n
Beta-sitosterol is a plant sterol found naturally in nuts, seeds, and vegetable oils. It’s the active ingredient in ProstaJet, dosed at 1,050 mg. Most of the research focuses on benign prostatic hyperplasia, or BPH<\/a>, the medical term for an enlarged prostate.<\/p>\n BPH affects most men over 50 and produces familiar symptoms: frequent urges to urinate, weak flow, and difficulty fully emptying the bladder.<\/p>\n The evidence for beta-sitosterol is about as solid as you’ll find for any supplement in this category. A systematic review in the Cochrane Library evaluated four randomized, placebo-controlled trials involving 519 men with BPH.<\/p>\n Beta-sitosterol improved both urinary symptom scores and flow measures, with a low rate of adverse events. Gastrointestinal side effects occurred in just 1.6% of participants.<\/p>\n The numbers are worth looking at specifically. Across the reviewed trials, beta-sitosterol was associated with a 4.9-point improvement on the International Prostate Symptom Score (IPSS), a clinically validated measurement tool, and an increase in peak urine flow of 3.91 mL\/s.<\/p>\n A 3-point IPSS change is generally considered clinically meaningful, so a 4.9-point improvement clears that bar.<\/p>\n Those results also held up over time. An 18-month follow-up study of men from an earlier double-blind, placebo-controlled trial found that participants who continued beta-sitosterol maintained stable symptom scores and flow measurements.<\/p>\n Beta-sitosterol is most useful for men with mild to moderate BPH symptoms. It does not reduce prostate size, and the existing studies have limitations: relatively short treatment durations and inconsistent standardization of the beta-sitosterol preparations used.<\/p>\n The long-term safety profile hasn’t been fully established, either. For men in the target age range experiencing the urinary symptoms associated with BPH, though, the clinical case is real.<\/p>\nWhat Does the Research Show?<\/h4>\n
Who Benefits Most from ProstaJet (Beta-Sitosterol)?<\/h4>\n